Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Average Price Target of $35.33 According to Analysts

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $35.33.

ODTX has been the subject of a number of recent research reports. Raymond James Financial initiated coverage on shares of Odyssey Therapeutics in a research note on Thursday, October 8th. They issued an “outperform” rating and a $42.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. HC Wainwright assumed coverage on Odyssey Therapeutics in a research report on Thursday, August 27th. They set a “buy” rating and a $44.00 target price on the stock. Weiss Ratings began coverage on Odyssey Therapeutics in a report on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. Finally, UBS Group began coverage on Odyssey Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $27.00 price target for the company.

Hedge Funds Weigh In On Odyssey Therapeutics

Several institutional investors have recently bought and sold shares of the business. State Street Corp acquired a new stake in Odyssey Therapeutics in the second quarter valued at approximately $1,477,000. Citadel Advisors LLC acquired a new position in shares of Odyssey Therapeutics during the second quarter worth $4,162,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Odyssey Therapeutics during the second quarter worth $601,000.

Odyssey Therapeutics Price Performance

ODTX opened at $18.88 on Friday. Odyssey Therapeutics has a 1-year low of $15.10 and a 1-year high of $29.05. The stock has a 50 day moving average price of $21.31.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Odyssey Therapeutics will post -6.08 earnings per share for the current fiscal year.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.